The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADI-PEG 20 plus docetaxel (DOC) in men with castrate resistant prostate cancer (CRPC): Results from a phase Ib trial.
 
Ben Kent Tomlinson
No Relationships to Disclose
 
John S. Bomalaski
Employment - Polaris
Leadership - Polaris
Stock and Other Ownership Interests - Polaris
 
Monica Diaz
Employment - Polaris
 
Taiwo Akande
No Relationships to Disclose
 
Tianhong Li
Speakers' Bureau - Pfizer
Research Funding - Astellas Pharma (Inst); Lilly (Inst); Novartis (Inst)
 
Thomas John Semrad
Consulting or Advisory Role - Amgen; Celgene; Genentech; Genomic Health; Onyx
Research Funding - Astex Pharmaceuticals (Inst); Eisai (Inst); Genentech (Inst); Millennium (Inst); Morphotek (Inst); Novartis (Inst)
 
Karen Kelly
Consulting or Advisory Role - Boehringer Ingelheim; Clovis Oncology; Daiichi Sankyo; Genentech; Lilly; Synta; Transgene
Research Funding - EMD Serono; Genentech; Lilly; Millennium; Novartis; Synta
Patents, Royalties, Other Intellectual Property - UpToDate
 
David R. Gandara
Honoraria - Array BioPharma; AstraZeneca; Celgene; Lilly; Novartis; Synta
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImClone Systems (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biomarin; Boehringer Ingelheim; Dava Oncology; Pfizer
 
Chong-xian Pan
Stock and Other Ownership Interests - Accelerated Medical Diagnostics; LP Therapeutics
Consulting or Advisory Role - Novartis
Research Funding - Abbott Diagnostics; Altor BioScience; Novartis
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst)